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trecht, Leiden, and Rotterdam, the Netherlands; and Reus, Spain
OBJECTIVES We investigated functional and structural markers of atherosclerosis in human immunodeficiency
virus (HIV)-infected patients in relation to the presence of the metabolic syndrome (MS).
BACKGROUND Antiretroviral combination therapy in HIV has been associated with cardiovascular risk
factors that cluster in the MS.
METHODS Thirty-sevenHIV-infected patients underwent assessment of flow-mediated vasodilation (FMD),
aortic pulse-wave velocity (PWV), and carotid intima-media thickness (IMT). Age-matched type
2 diabetic patients (n  13) and healthy controls (n  14) served as reference groups.
RESULTS Fifteen HIV-infected patients (41%) fulfilled the National Cholesterol Education Program
criteria of the MS. The FMD was similarly impaired in HIV-infected patients without the
MS (MS group) and the diabetic patients (5.1  0.4% and 4.9  0.6%, respectively)
compared with controls (8.8 0.7%). The HIV-infected patients with the MS (MS group)
had even more impaired FMD (2.5  0.3%). Carotid IMT was similarly increased in the
MS group and the diabetic patients compared with the other groups. Aortic PWV was
increased in the diabetic patients only. In HIV-infected patients, FMD was related to
metabolic parameters, whereas aortic PWV and IMT were related to parameters of HIV
infection, time on antiretroviral combination therapy, inflammatory (C-reactive protein and
leukocytes) and metabolic parameters.
CONCLUSIONS The data of the present study suggest an increased cardiovascular risk in HIV-infected
patients, even in the absence of clustering of metabolic risk variables. The presence of the MS
in HIV is associated with even more advanced atherosclerotic changes. Presumably, both
HIV infection and antiretroviral therapy may promote atherosclerosis through mechanisms
involving endothelial cells, either directly or indirectly via metabolic risk factors. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.073Cardiol 2006;47:1117–23) © 2006 by the American College of Cardiology Foundation
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she use of highly active antiretroviral therapy (HAART) in
uman immunodeficiency virus (HIV) has been associated
ith insulin resistance, glucose intolerance, unfavorable fat
istribution, and dyslipidemia (1–4). The clustering of these
isk factors shows striking similarities with the metabolic
yndrome (MS), as described in HIV-negative individuals
5). The increasing prevalence of the MS in HIV is cause for
See page 1124
oncern because the MS is associated with an increased risk
or cardiovascular disease (CVD) (5). As survival of patients
ith HIV increases, CVD may become an important
omplication in the management of these patients. Despite
he close relationship between HAART and metabolic risk
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ccepted September 20, 2005.actors, controversy surrounding HIV infection and CVD
till exists. For example, in a large retrospective study,
AART was associated with a large benefit in terms of
cquired immunodeficiency syndrome (AIDS)-related mortal-
ty that was not diminished by any increase in the rate of
ardiovascular events or related mortality (6). However, in a
ulticenter prospective study, HAART was independently
ssociated with a 26% relative increase in the rate of
yocardial infarction per year of antiretroviral drug expo-
ure during the first four to six years of use (7).
Endothelial dysfunction is an early marker of atheroscle-
osis and can be assessed clinically by ultrasound assessment
f brachial artery flow-mediated vasodilation (FMD). Flow-
ediated vasodilation is correlated with the severity and
xtent of coronary sclerosis (8), and predicts future cardio-
ascular events (9). Ultrasound measurement of carotid
ntima-media thickness (IMT) is a well-accepted, noninva-
ive method of assessing early changes in vascular structure,
nd is widely used as a surrogate marker for atherosclerotic
isease (10). Aortic pulse-wave velocity (PWV) is a nonin-
asive measurement of arterial stiffness, and is associated
ith end-organ alterations, such as increased ventricular
tress and arterial intima-media thickening (11). Aortic
WV is also an independent predictor of cardiovascular
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clerotic markers may provide important information on
oth functional and structural stages of atherosclerosis.
In a cross-sectional study of HIV-infected adults, it was
hown that those on a protease inhibitor (PI)-containing
egimen had markedly impaired FMD compared with those
ot taking PIs (13). However, in that study, FMD was not
ompared with an HIV-negative reference group, and the
elative contributions of antiretroviral agents, chronic in-
ammation attributable to viral infection, and metabolic risk
actors and their interactions were difficult to identify.
tructural vascular abnormalities are also present in patients
ith HIV infection. Carotid IMT is higher in HIV patients
han in age-matched control patients (14,15), and progresses
uch more rapidly than previously reported rates in non-
IV cohorts (16). Arterial stiffness has not been investi-
ated in HIV-infected adults. Clearly, most studies using
ntermediate CVD end points suggest an increased risk for
remature atherosclerosis in HIV-infected patients.
It is becoming increasingly important to identify those
IV-infected patients who have the highest risk for ath-
rosclerosis. However, there is still a lack of studies on
ardiovascular risk assessment using established intermedi-
te end points in HIV-infected patients. In the present
tudy, we investigated FMD, aortic PWV, and IMT in
IV-infected men on stable HAART and subdivided the
roup into those with and without the MS as defined by the
ational Cholesterol Education Program-Adult Treatment
anel III (NCEP-ATPIII) guidelines (17). In addition, we
elated these well-established parameters of the vasculature
o clinically easily obtainable anthropometric, hemody-
amic, and laboratory parameters. The data were compared
ith data from age-matched type 2 diabetic patients, who
re known to have a marked increased cardiovascular risk
18), and healthy men as controls.
ATIENTS AND METHODS
atients. Men between 18 and 70 years old with a docu-
ented HIV infection were recruited from the Department
Abbreviations and Acronyms
AIDS  acquired immunodeficiency syndrome
CCA  common carotid artery
CRP  C-reactive protein
CVD  cardiovascular disease
FMD  flow-mediated vasodilation
HAART  highly active antiretroviral therapy
HIV  human immunodeficiency virus
IGT  impaired glucose tolerance
IMT  intima-media thickness
MS  metabolic syndrome
NCEP-ATPIII  National Cholesterol Education
Program-Adult Treatment Panel III
PI  protease inhibitor
PWV  pulse-wave velocityf Infectious Disease of the University Medical Center ftrecht. Inclusion criteria were HIV-RNA 10.000 cop-
es/ml and HAART for at least 12 months. Exclusion
riteria were the presence of opportunistic infectious disease
nd/or malignancies, renal and/or liver disease, diabetes
ellitus, and the use of lipid-lowering and/or antihyperten-
ive agents. The study protocol was approved by the local
esearch ethics committee of the University Medical Center
trecht. All participants gave written informed consent.
he data on FMD and aortic PWV were compared with
ata from 15 age-matched type 2 diabetic and 15 healthy
en. The diabetic patients were all treated with oral
ntihyperglycemic agents (four with sulfonylureum deriva-
ives, four with metformin, and five with a combination of
oth) and had glycated hemoglobin 9%. None of the
iabetic patients were taking statins and/or antihypertensive
gents. Furthermore, the diabetic patients and the healthy
ontrols met the same inclusion criteria as the HIV-infected
atients. At inclusion, length, weight, blood pressure, and
aist and hip circumference were measured.
ral glucose tolerance test. A standard oral glucose tol-
rance test was performed in the HIV-infected patients
nly. The patients visited our department after a 10-h fast.
fter placing a cannula for venous blood sampling, patients
ested for 15 min before administration of the glucose load
75 g). Peripheral blood samples were obtained in sodium
thylenediaminetetraacetic acid (2 mg/ml) before and at
egular 30-min intervals up to 2 h after glucose ingestion.
ll samples were kept on ice and centrifuged immediately
or 15 min at 800 g at 4°C and stored at 80°C until assay.
ndothelial function. Nitric oxide-dependent FMD, as
ercentage diameter change in the brachial artery after
eactive hyperemia, was measured noninvasively by ultra-
onography (19). Measurements were performed at the
lbow of the right arm using a vessel wall movement system
Wall Track System, Pie Medical, Maastricht, the Nether-
ands), which consists of an ultrasound imager with a
0-MHz linear array transducer connected to a data acqui-
ition system and a personal computer. Three measurements
ere averaged to calculate a baseline diameter of the
rachial artery. By inflation of a blood pressure cuff for 5
in at a pressure of 200 mm Hg, ischemia was applied to
he forearm distal to the location of the transducer. Ultra-
onography continued for 5 min after cuff release, with
easurements at 30-s intervals. The widest lumen diameter
as taken as a measurement for maximal vasodilation.
itroglycerin (400 g) was used to determine endothelium-
ndependent vasodilation. All measurements were per-
ormed by the same technician with patients supine in a
uiet, temperature-controlled (20°C to 22°C) environment
fter at least 15 min of rest. All patients were requested to
efrain from smoking on the morning of the vascular
easurements.
WV. Arterial stiffness was assessed noninvasively by aor-
ic PWV (20). Aortic PWV was calculated as distance/
ransit time (in centimeters per second) of the pulse wave
rom the base of the neck from the common carotid to the
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March 21, 2006:1117–23 Functional and Structural Markers of Atherosclerosis in HIVight femoral artery. The pulse waves at each of these sites
ere obtained sequentially with a tonometric sensor
Sphygmocor, Atcor Medical, Sydney, Australia). Pulse
ransit time was determined as the average of 10 consecutive
eats. The distance traveled by the pulse waveform was
easured over the participant’s torso. The validation of this
utomatic method and its reproducibility have been pub-
ished previously (20). The measurements were performed
wice in each patient and then averaged to obtain the mean
ortic PWV, which was used for the statistical analysis.
arotid IMT. To measure carotid IMT, ultrasonography
f the left and right common carotid artery (CCA) was
erformed with a 10-MHz linear-array transducer (ATL
ltraMark IV). In accordance with the Rotterdam Study
ltrasound protocol (21), a careful search was performed for
ll interfaces of the anterior (near) and posterior (far) walls
f the distal CCA. The optimal longitudinal image was
rozen on the R wave of the electrocardiogram and stored on
ideotape. This procedure was repeated four times for both
ides. From the videotape, the frozen images were digitized
nd displayed on the screen of a personal computer using
dditional dedicated software (22). With a cursor, the
nterfaces of the distal CCA were marked across a length of
0 mm. The beginning of the dilatation of the distal CCA
erved as a reference point for the start of the measurement.
he average of the IMT of each of the four frozen images
as calculated. For each individual, the IMT was deter-
ined as the average of near- and far-wall measurements of
oth the left and right arteries. The reproducibility of IMT
easurements has been previously described (22). Measure-
ent of IMT was performed in the HIV-infected patients
nly.
nalytical methods. Total and high-density lipoprotein
holesterol, triglycerides, apolipoprotein B, glucose, and
lycated hemoglobin were measured using standard labora-
ory procedures. Ultracentrifugation was used to isolate
ow-density lipoprotein. Insulin was measured by enzyme-
inked immunosorbent assay (Mercodia, Uppsala, Sweden).
lood leukocyte counts were determined automatically us-
ng a Celldyn-3500 (Abbott, Abbott Park, Illinois). Plasma
-reactive protein (CRP) was measured using a high
ensitivity method (Quantex hs-CRP kit, Biokit, S. A.,
arcelona, Spain), with a lower limit of detection of 0.10
g/l. The HIV viral load was determined by ultrasensitive
ssay (Roche Diagnostics Amplicor HIV-1 Monitor assay,
leasanton, California), and CD4 cell counts were deter-
ined by flow cytometry.
tatistical analysis. Data are expressed as mean (SEM) in
he text, tables, and figures. The NCEP-ATPIII guidelines
ere used to identify patients with the MS (17). The MS
as present when at least three of five risk determinants
increased waist circumference, increased blood pressure,
levated fasting triglyceride level, low high-density lipopro-
ein cholesterol, and elevated fasting glucose level) were
resent. Differences between two groups were tested with
ann-Whitney tests. Comparisons between three groups
v
ir more were performed with one-way analysis of variance,
ith the least significance difference test as post hoc analysis
est. Bivariate correlations for the total group of HIV-
nfected patients were calculated using Spearman’s correla-
ion coefficients. All significantly correlated variables were
sed as independent variables in stepwise multiple regres-
ion analysis with FMD, aortic PWV and IMT as depen-
ent variables. Calculations were performed using SPSS/PC
11.5 (SPSS Inc., Chicago, Illinois). Statistical signifi-
ance was taken as the 5% level.
ESULTS
haracteristics of the study group. Of the 37 HIV-
nfected patients included in the study, 15 (41%) fulfilled
he NCEP-ATPIII criteria for having the MS. Elevated
asting plasma triglyceride level (68%), increased blood
ressure (54%), and low high-density lipoprotein choles-
erol (41%) were the most prevalent components of the MS,
hereas high fasting glucose level (3%) and a high waist
ircumference (5%) were less prevalent. None of the healthy
ontrols fulfilled the criteria for having the MS, whereas all
ype 2 diabetic patients had the MS. All HIV-infected
atients were currently receiving HAART with nucleoside
everse transcriptase inhibitors and a PI and/or a non-
ucleoside reverse transcriptase inhibitor (Table 1). Baseline
haracteristics and metabolic profile of the HIV-infected
roups, the diabetic patients (n  13), and the healthy men
n  14) are shown in Table 2. Apolipoprotein B was
imilarly increased in the diabetic patients and the MS
roup as compared with the healthy controls, and it was
ighest in the MS group. Nine HIV-infected patients (all
n the MS group) had impaired glucose tolerance (IGT).
unctional and structural vascular assessment. Hemody-
amic, inflammatory, and vascular parameters of the study
roup are shown in Table 3. Baseline brachial artery lumen
iameter measurements were not different between the
roups (Table 3). Flow-mediated vasodilation was similarly
mpaired in the MS group and the diabetic patients
ompared with the control patients (Fig. 1A). The MS
roup had even more impaired FMD than the MS group
able 1. Virologic and Immunologic Characteristics and
AART of the HIV-Infected Patients
MS Group
(n  15)
MS Group
(n  22)
ime since diagnosis of HIV (yrs) 8.5 (0.8) 7.5 (5.2)
ime on HAART (yrs) 4.8 (0.5) 4.2 (0.6)
D4 cell count (106 cells/l) 604 (105) 719 (58)
IV viral load (copies/ml) 1114 (824) 813 (201)
IV viral load 50, n (%) 12 (80%) 17 (77%)
rotease inhibitors, n (%) 10 (67%) 15 (68%)
NRTI, n (%) 5 (33%) 7 (32%)
RTI, n (%) 15 (100%) 22 (100%)
ata are mean (SEM), unless otherwise indicated. There were no differences in
irologic and immunologic parameters and HAART between the groups.
HAART highly active antiretroviral therapy; HIV human immunodeficiencyirus; MS  metabolic syndrome; NNRTI  non-nucleoside reverse transcriptase
nhibitor; NRTI  nucleoside reverse transcriptase inhibitor.
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Functional and Structural Markers of Atherosclerosis in HIV March 21, 2006:1117–23nd the diabetic patients. Endothelium-independent vaso-
ilation was higher in the control patients than in the other
roups. The diabetic patients had increased aortic PWV
ompared with the other groups (Fig. 1B), but no difference
n aortic PWV was observed between the MS group and
he MS group. The HIV-infected patients with IGT (n
) had increased aortic PWV compared with those with
ormal glucose tolerance (9.2 0.7 cm/s vs. 7.7 0.6 cm/s,
 0.03). The patients on a PI-containing regimen (n 
5) had a tendency toward more impaired FMD compared
ith those not taking PIs (n 12, 4.1 0.4% vs. 5.3 0.6%,
espectively, p  0.09), but similar aortic PWV (8.1  1.1
m/s vs. 7.9  0.9 cm/s, respectively). Carotid IMT was
ncreased in the MS group and the diabetic group
ompared with the other groups (Fig. 1C).
eterminants of vascular measurements in HIV-infected
atients. Correlations between the vascular measurements
nd anthropometric, hemodynamic, and laboratory param-
ters for the total group of HIV-infected patients (n  37)
able 2. Characteristics of HIV-Infected Patients With (MS G
ype 2 Diabetic Patients, and Healthy Control Patients
MS Group
(n  15)
MS Group
(n  22)
ge (yrs) 50 (3) 47 (2)
ody mass index (kg/m2) 24.4 (0.5)† 23.6 (0.4)
aist circumference (cm) 94 (2)† 92 (2)
aist-to-hip ratio 1.00 (0.02)* 0.98 (0.01)*
moking, n (%) 2 (13%) 3 (14%)
otal cholesterol (mmol/l) 6.2 (0.2)*†‡ 5.4 (0.2)
DL cholesterol (mmol/l) 2.99 (0.2) 3.30 (0.2)
DL cholesterol (mmol/l) 1.05 (0.05)* 1.18 (0.05)*
riglycerides (mmol/l) 3.82 (0.74)*† 2.01 (0.43)*
polipoprotein B (g/l) 1.29 (0.05)*†‡ 1.03 (0.04)*
lycated hemoglobin (%) 5.2 (0.1)† 5.2 (0.1)
asting glucose (mmol/l) 5.4 (0.3)† 5.1 (0.2)
asting insulin (mU/l) 9.0 (1.4)*‡ 5.8 (1.4)
-h glucose (mmol/l) 8.0 (0.7) 6.5 (0.3)
-h insulin (mU/l) 74.6 (18.9)‡ 29.9 (6.8)
ata are mean (SEM). The criteria of the metabolic syndrome (waist, triglycerides, a
p  0.05 versus healthy men; †p  0.05 versus diabetic patients; ‡p  0.05 versus
HDL  high-density lipoprotein; LDL  low-density lipoprotein; ND  not d
able 3. Hemodynamic, Inflammatory, and Vascular Parameters
MS Group) the Metabolic Syndrome, Type 2 Diabetic Patient
MS Group
(n  15)
MS Gro
(n  22)
ystolic BP (mm Hg) 140 (4) 127 (2)
iastolic BP (mm Hg) 84 (2) 80 (2)
ean arterial pressure (mm Hg) 104 (2) 96 (2)
RP (mg/l) 5.8 (1.7)* 3.9 (1.0)*
lood leukocyte count (cells 109/l) 7.3 (2.4)* 6.7 (2.0)*
Neutrophils (cells 109/l) 4.1 (0.5)* 3.6 (0.3)*
Lymphocytes (cells 109/l) 2.4 (0.2)*† 2.4 (0.2)*
Monocytes (cells 109/l) 0.64 (0.05) 0.59 (0.05
rachial artery lumen diameter (mm) 4.56 (0.17) 4.45 (0.13
TG (%) 12.2 (1.6)* 13.0 (1.5)*
ata are mean (SEM). The criteria of the metabolic syndrome (SBP and DBP) wer
en; †p  0.05 versus diabetic patients; ‡p  0.05 versus MS group.
BP  blood pressure; CRP  C-reactive protein; DBP  diastolic blood pressure;
able 2.re shown in Table 4. Using stepwise multiple regression
nalysis, FMD was best predicted by apolipoprotein B
standardized beta  0.30, p  0.01), explaining 40% of the
ariation. Aortic PWV was best predicted by the mean arterial
ressure (standardized beta  0.14, p  0.03) and the
wo-hour glucose concentration (standardized beta  0.24,
 0.02), explaining 73% of the variation. Age (standardized
eta 0.54, p 0.02), apolipoprotein B (standardized beta
.44, p  0.03), and HIV viral load (standardized beta 
.33, p  0.04) were the best predictors of IMT, explaining
6% of the variation. In both the HIV-infected patients and
he diabetic patients, glycated hemoglobin levels were not
ssociated with the vascular measurements (data not
hown).
ISCUSSION
s the survival of patients with HIV increases, it is
ecoming increasingly important to identify those patients
) and Without (MS Group) the Metabolic Syndrome,
ype 2 Diabetic Men
(n  13)
Healthy Men
(n  14)
p Value From
Analysis of Variance
56 (2)‡ 52 (3) 0.35
29.3 (1.1)*‡ 25.2 (0.7) 0.03
102 (3)*‡ 94 (3) 0.02
0.98 (0.02)* 0.93 (0.02) 0.01
1 (15%) 2 (14%) 0.88
5.1 (0.2) 4.9 (0.3) 0.02
3.17 (0.25) 2.97 (0.19) 0.21
1.10 (0.13)* 1.58 (0.11) 0.04
2.00 (0.40)* 1.03 (0.10) 0.02
0.94 (0.07)* 0.82 (0.04) 0.02
6.1 (0.2)*‡ 4.58 (0.1) 0.03
7.6 (0.4)*‡ 4.8 (0.3) 0.01
12.9 (2.1)*‡ 4.2 (1.2) 0.01
ND ND
ND ND
L cholesterol) were not statistically analyzed between the MS and MS groups.
group.
ned; other abbreviations as in Table 1.
IV-Infected Patients With (MS Group) and Without
d Healthy Control Patients
Type 2 Diabetic Men
(n  13)
Healthy Men
(n  14)
p Value From
Analysis of Variance
148 (3)*‡ 133 (2) 0.03
89 (2)‡ 87 (2) 0.04
109 (3)‡ 103 (2) 0.03
3.2 (1.7)* 1.15 (0.66) 0.007
6.3 (1.9)* 5.6 (1.4) 0.02
3.7 (0.3)* 3.1 (0.3) 0.04
1.9 (0.1) 1.8 (0.1) 0.03
0.54 (0.08) 0.40 (0.06) 0.12
4.67 (0.14) 4.40 (0.09) 0.67
12.6 (1.8)* 19.4 (2.0) 0.02
statistically analyzed between the MS and MS groups. *p  0.05 versus healthyroup
T
nd HDof H
s, an
up
†
)
)
e notNTG  nitroglycerin; SBP  systolic blood pressure; other abbreviations as in
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March 21, 2006:1117–23 Functional and Structural Markers of Atherosclerosis in HIVho are at increased risk for accelerated atherosclerosis. In
he present study, we determined the relationship between
ntermediate end points of CVD and clinically easily ob-
ainable anthropometric, hemodynamic, and laboratory pa-
ameters in HIV-infected patients. Our main findings are
hat HIV-infected patients without the MS have endothe-
ial dysfunction similar to that of type 2 diabetic patients.
he presence of the MS in HIV was associated with even
ore advanced functional and structural vascular abnormal-
ties.
In the present study, 41% of the patients fulfilled the
efinition of the MS according to the NCEP-ATPIII
igure 1. Mean flow-mediated vasodilation (FMD) (A), aortic pulse-wave
elocity (PWV) (B), and carotid intima-media thickness (IMT) (C) in
uman immunodeficiency virus (HIV)-infected patients with the meta-
olic syndrome (MS group) and without the metabolic syndrome (MS
roup), type 2 diabetic patients, and healthy controls. *p  0.05 versus
ealthy controls. †p  0.05 versus type 2 diabetic patients. ‡p  0.05
ersus MS group. §p  0.05 versus MS group.uidelines. In the U.S., approximately 24% of the general population fulfills this definition (23). Elevated triglyceride
evels were the most prevalent component of the MS,
hereas an increased waist circumference and high fasting
lasma glucose level were less prevalent. Despite normal
asting glucose levels, 24% of the HIV-infected patients had
GT (24%). On average, both HIV-infected groups had a
ormal waist circumference (102 cm) but a relatively high
aist-to-hip ratio. Therefore, the presentation of the MS in
IV-infected patients may differ from that in the general
opulation because of differences in body composition and
irect effects of antiretroviral agents on glucose and lipid
omeostasis. We have chosen to use the NCEP definition
or the MS because these criteria do not include oral glucose
olerance test and urinary albumin level, making it more
asily applicable for routine screening of HIV-infected
atients than the World Health Organization definition
24).
Atherosclerosis is characterized by and preceded by en-
othelial dysfunction (8,9). In the present study, HIV-
nfected patients without the MS showed endothelial dys-
unction comparable to that of age-matched type 2 diabetic
atients, who are known to have a marked increased risk for
VD (18). These data suggest an increased CVD risk in
IV-infected patients, even in the absence of metabolic risk
ariable clustering. Several factors may explain this obser-
ation. First, in HIV-infected patients, the endothelium
ould be activated either directly by HIV or by a leukocyte-
ediated inflammatory cascade triggered by HIV infection.
everal studies have shown that HIV-associated proteins
gp120 and Tat) interact with chemokine receptors and
nduce endothelial cell apoptosis (25,26). Endothelial acti-
ation may also occur by cytokines secreted in response to
eukocyte activation by HIV (27–29). We observed elevated
lood leukocyte counts and elevated CRP levels in the
able 4. Spearman Correlation Coefficients (r) Between
ascular Measurements and Other Parameters for the Total
roup of HIV-Infected Patients (n  37)
FMD
Aortic
PWV
Carotid
IMT
ge 0.39*
ime since diagnosis of HIV 0.40*
ime on HAART 0.38* 0.38*
IV viral load 0.47†
RP 0.33*
lood leukocyte count 0.38*
ystolic blood pressure 0.32* 0.40* 0.35*
iastolic blood pressure 0.43*
ean arterial pressure 0.45†
riglycerides 0.33*
holesterol 0.42* 0.38*
polipoprotein B 0.46† 0.43*
asting glucose 0.36*
-h glucose 0.40* 0.36*
asting insulin 0.37*
-h insulin 0.35*
nly significant correlation coefficients are given. *p  0.05; †p  0.01.
FMD  flow-mediated vasodilation; IMT  intima-media thickness; PWV 
ulse-wave velocity; other abbreviations as in Table 3.
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une activation associated with HIV infection (27–29).
owever, in addition to chronic immune activation, CRP
evels have also been related to body composition in HIV-
nfected patients (30). In HIV-negative patients, both
eukocyte counts and CRP have been linked to endothelial
ysfunction and future cardiovascular events (31–34). Sec-
nd, it should be noted that the MS group was charac-
erized by high apolipoprotein B levels, despite the absence
f other metabolic risk factors, and apolipoprotein B was
lso closely related to endothelial dysfunction in our study.
his may be attributable to direct inhibitory effects of PI on
roteosomal apolipoprotein B degradation in the liver (35).
hird, antiretroviral agents may also directly induce endo-
helial dysfunction. For example, when healthy volunteers
ere given indinavir for four weeks, significant endothelial
ysfunction was observed, independent of the lipid profile
36). Whether this effect also occurs in HIV-infected patients
s not known. In our study, the patients on a PI-containing
egimen showed a tendency toward more pronounced endo-
helial dysfunction compared with those on a non-nucleoside
everse transcriptase inhibitor-containing regimen, which may
e significant if repeated in a larger group.
The nitroglycerin response was lower in both the HIV-
nfected and the diabetic patients compared with the control
atients. Impaired smooth muscle responsiveness has been
bserved previously in patients with type 2 diabetes (37). No
ifference in nitroglycerin responsiveness was observed be-
ween both HIV-infected groups and the diabetic patients,
llowing comparisons in endothelial function assessed by
MD between these groups.
In our study, we excluded patients with HIV-RNA
10,000 copies/ml and patients with AIDS-related dis-
ases. Lymphocyte counts were normal in our group of
IV-infected patients, whereas these are generally low in
ntreated HIV-infected patients and in patients with AIDS-
elated diseases. Almost 80% of the patients had HIV-RNA
50 copies/ml. However, some patients had discordant
esponses in virologic and immunologic parameters. Viro-
ogic failure, immunologic failure, and clinical progression
ave distinct time courses and may occur independently or
imultaneously. In patients with a history of extensive prior
reatment and drug resistance, complete viral suppression is
ften difficult to achieve. Thus, the goal is to preserve
mmunologic function and prevent clinical progression,
ven with ongoing viremia. Even partial virologic suppres-
ion of HIV-RNA correlates with clinical benefits probably
ttributable to diminished viral fitness.
As expected, the presence of the MS was associated with
ore severe endothelial dysfunction, as well as a marked
ncreased IMT, in our cohort of HIV-infected men, sug-
esting more advanced functional and structural atheroscle-
otic changes. Hence, the NCEP-ATPIII criteria of the
S may also be used in HIV-infected patients to identify
atients at risk for accelerated atherosclerosis. Other obser-
ational studies have shown that IMT in HIV-infectedatients is related to several traditional risk factors (14–16),
ut when a control group was added to the analysis, HIV
nfection was also an independent predictor of IMT (16).
urthermore, progression of IMT has been related to nadir
D4 counts (200) (16), which were unfortunately not
vailable for most of our patients. We did not find a
elationship between vascular parameters and the actual
D4 cell count, but the results of our study suggest that
etabolic, virologic and inflammatory parameters, time
ince diagnosis of HIV infection, and time on HAARTmay
ontribute to structural atherosclerotic changes in HIV-
nfected patients. It must be noted that we only measured
ntermediate markers of CVD, and not CVD end points.
evertheless, given the observed metabolic profile and
ascular abnormalities, at least a number of HIV-infected
atients in our study group would be eligible for lipid-
owering therapy.
The presence of the MS per se was not associated with
ncreased arterial stiffness, despite impaired endothelial
unction and increased IMT in these patients. In contrast,
he HIV-infected patients with IGT (n  9) showed
ncreased aortic PWV comparable to that of type 2 diabetic
atients. This may suggest that increased arterial stiffness is
onfined to HIV-infected patients with deteriorating glu-
ose tolerance status. Previous studies support a close
elationship between IGT, type 2 diabetes, and arterial
tiffness (38,39). The close associations between aortic
WV and the two-hour glucose concentration and insulin
ensitivity support this concept. Aortic PWV was also
ssociated with the time since diagnosis of HIV infection
nd the time on HAART.
In summary, endothelial function is disturbed in HIV-
nfected patients, even in the absence of metabolic risk variable
lustering. The presence of the MS is associated with even
ore advanced atherosclerotic changes in HIV-infected pa-
ients. Presumably, both HIV infection and antiretroviral
herapy may promote atherosclerosis through mechanisms
nvolving endothelial cells, either directly or indirectly via
etabolic risk factors. Future studies are necessary to in-
estigate whether treatment of metabolic risk factors could
ead to reduced cardiovascular risk in these patients.
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